The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 April 2026•

1 min read

ADMA Biologics Shares Plunge 29% Amid Securities Fraud Investigation

Key Facts

1ADMA Biologics shares dropped 29% amid claims of 'channel stuffing'.

2Law firm Bleichmar Fonti & Auld LLP launched an investigation into potential federal securities law violations.

3Investors are being urged to contact the law firm regarding a potential class action lawsuit.

ADMA Biologics (NASDAQ: ADMA) shares experienced a sharp decline of 29% following allegations of financial impropriety. The sell-off was triggered by claims of 'channel stuffing,' a practice allegedly used to artificially inflate sales figures. In response, the law firm Bleichmar Fonti & Auld LLP announced a formal investigation into potential violations of federal securities laws. The investigation aims to determine if the company misled investors regarding its financial health and operational performance. Investors who suffered significant losses are being encouraged to contact the firm to participate in a potential class action lawsuit. This development has severely damaged investor confidence and raised concerns about the company's future transparency and legal liabilities.

Create Free Account